Avidity Biosciences Inc. (NASDAQ: RNA) is a clinical-stage biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs) for targeted RNA therapeutics. Its pipeline addresses rare muscle diseases such as myotonic dystrophy and facioscapulohumeral muscular dystrophy. By combining tissue-specific delivery with genetic modulation, Avidity aims to overcome traditional RNA therapy limitations. The company offers investors high-upside exposure to next-generation genetic medicine with strong scientific validation and pharma interest.
Τελευταία άρθρα για μετοχές